Georgia Allowed Product Forms — Oils, Tinctures, Capsules, Lozenges, Topicals, Patches

Last verified: May 2026

The Six Permitted Product Forms

Under current Georgia law (codified at O.C.G.A. § 16-12-191 and refined by SB 195 of 2021), the only legal forms of medical cannabis in Georgia are:

1. Oils — The Original 2015 Form

Cannabidiol-rich oils with up to 5% THC by weight. The original form authorized in 2015 by Haleigh’s Hope Act. Available in dropper bottles, typically 30 ml or 60 ml. Patients dose by milliliter, calibrated to milligrams of total THC and CBD per dose. Most patients use sub-lingual administration (under the tongue, held for 30–60 seconds) for fast onset.

2. Tinctures

Alcohol- or oil-based extracts. Functionally similar to oils for sub-lingual use; difference is primarily in carrier and flavoring. Authorized by SB 195 of 2021.

3. Capsules

Pre-measured oral capsules, typically 5 mg, 10 mg, 25 mg, or 50 mg of THC per capsule. CBD-only and CBD/THC blend capsules also available. Slower onset (30 min to 2 hours) than sub-lingual oils; longer effect duration.

4. Lozenges

Dissolvable cannabinoid-infused lozenges. Slower onset than sub-lingual oils, faster than capsules. The lozenge form is the closest legal Georgia analog to "edible" products in other state programs — but conventional edibles (cookies, brownies, candies, gummies) are not authorized.

5. Topicals

Salves, lotions, body butters, and pain-relief sticks. Topicals are non-psychoactive (cannabinoids do not cross the skin barrier into systemic circulation in meaningful amounts). Particularly common for arthritis, peripheral neuropathy, and localized inflammation.

6. Transdermal Patches

Adhesive patches that deliver cannabinoids systemically over an 8-to-12-hour window. Less common than topicals; useful for sustained-release dosing for chronic-pain or sleep applications.

What Is EXPLICITLY Prohibited

The following are not authorized under any provision of Georgia’s medical-cannabis statute:

• Smokable flower. No buds, pre-rolls, or shake. Even cardholders may not legally possess cannabis flower.
• Vaporization / vape cartridges. SB 220 (2026) would authorize vaporization for 21+ no later than January 1, 2027. Until then, vapes remain prohibited.
• Conventional edibles. Cookies, brownies, candies, gummies (the dominant edible categories in most state programs) are explicitly prohibited.
• Any preparation exceeding 5% THC by weight, with CBD content equal to or greater than the THC content. The 5% cap with CBD≥THC requirement is the lowest of any U.S. state program. See 5% THC cap page.

SB 195 (2021) — The Product-Form Expansion

SB 195 of 2021 expanded the original "oil" definition to authorize tinctures, capsules, lozenges, transdermal patches, and topicals. Before SB 195, only oils were authorized — a tighter restriction that excluded patient-friendly forms like lozenges and patches.

Why No Smokable Flower

The legislative compromise that produced Haleigh’s Hope Act in 2015 was structured around oil-form medical cannabis only. Gov. Deal’s requirement that in-state cultivation be stripped from HB 1 was paired with the oil-form restriction; the political bargain was that the program would never look like a "smoking" program. Even after HB 324 of 2019 authorized in-state production, the 2015 product-form architecture remained unchanged.

SB 220 (2026) breaks this compromise on vaporization (for 21+ patients in private settings). Whether subsequent legislation will authorize smokable flower remains an open question; SB 220 itself does not authorize smokable flower.

Practical Patient Notes

• Sub-lingual oils are the fastest-onset legal product form (~10–30 minute onset).
• Capsules offer precise dosing but slower onset (30 min–2 hours).
• Topicals are non-psychoactive and useful for localized pain.
• Transdermal patches are useful for sustained chronic-pain or sleep applications.
• The 5% cap means patients dose by larger volume of product than in higher-cap states — the 20 fl oz possession ceiling is calibrated to multi-month dosing for chronic conditions.
• If SB 220 is signed: vaporization (not smoking) will be authorized for patients 21+, no later than January 1, 2027, in private settings. Vapes will join the legal product menu.

Lab Testing & Labeling

All Georgia medical-cannabis products must be tested for:

• Potency — total THC and total CBD must satisfy the 5% / CBD≥THC requirement.
• Pesticides, heavy metals, microbials, residual solvents — standard medical-cannabis safety testing.

Labels must conspicuously display total THC and total CBD per serving and per package, plus the standardized health-warning language regarding pregnancy, driving, machinery operation, and minors.